| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3508902 | ADME | Inhibitory activity of 20 uM SPP100 on 39 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 2. | ALA3508903 | ADME | Inhibitory activity of 20 uM SPP100 on 37 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 3. | ALA3508904 | ADME | Inhibitory activity of 20 uM SPP100 on 37 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 4. | ALA3508905 | ADME | Inhibitory activity of 200 uM SPP100 on 37 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 5. | ALA3508906 | ADME | Inhibitory activity of 200 uM SPP100 on 37 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 6. | ALA3508907 | ADME | Inhibitory activity of 200 uM SPP100 on 34 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 7. | ALA3508908 | ADME | Inhibitory activity of 100 uM tranylcypromine on 1.2 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 8. | ALA3508909 | ADME | Inhibitory activity of 100 uM tranylcypromine on 0.6 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 9. | ALA3508910 | ADME | Inhibitory activity of 100 uM tranylcypromine on 0.3 Pmoles of cDNA-derived CYP2A6 enzyme in microsome prepared from human lymphoblastoid cell line | Homo sapiens | 1 | ALA3508693 | microsome format | FDA Approval Packages | |
| 10. | ALA3539249 | ADME | Activity of human recombinant CYP2A6 expressed in microsomes isolated from human AHH-1 cells assessed as enzyme-mediated 3-(2,4-dimethylphenylthio)-4-(piperazin-1-yl)phenol formation at 8 to 50 uM after 120 mins by HPLC/MS-MS analysis in presence of NADPH regenerating system with NADP+ | Homo sapiens | 1 | ALA3525899 | cell-based format | Scientific Literature | |
| 11. | ALA3539939 | ADME | Inhibition of CYP2A6 in human liver microsomes using coumarin as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis | Homo sapiens | 1 | ALA3526034 | assay format | Scientific Literature | |
| 12. | ALA3540101 | ADME | Drug metabolism in human liver microsomes assessed as monoclonal antibody-mediated inhibition of CYP2A6-mediated (R)-1-(4-(4-fluoro-2-(hydroxymethyl)-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yloxy)propan-2-ol formation at 2 and 20 uM for 30 mins by LC/MS analysis | Homo sapiens | 1 | ALA3526086 | assay format | Scientific Literature | |
| 13. | ALA3541695 | ADME | Drug level in human recombinant CYP2A6 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis | Homo sapiens | 2 | ALA3526081 | cell-based format | Scientific Literature | |
| 14. | ALA3537631 | ADME | Activity of recombinant human CYP2A6 expressed in Escherichia coli JM109 co-expressing P450 reductase assessed as enzyme-mediated drug metabolism measured as compound remaining after 1 hr by LC-MS analysis | Homo sapiens | 1 | ALA3526051 | assay format | Scientific Literature | |
| 15. | ALA3537632 | ADME | Activity of recombinant human CYP2A6 expressed in Escherichia coli JM109 co-expressing P450 reductase assessed as enzyme-mediated drug metabolism treated with LBH589 measured after 1 hr by LC-MS analysis | Homo sapiens | 5 | ALA3526051 | assay format | Scientific Literature | |
| 16. | ALA3535048 | ADME | Activity of recombinant human CYP2A6 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated compound depletion at 0.02 uM after 30 mins by LC-MS analysis | Homo sapiens | 1 | ALA3525951 | assay format | Scientific Literature | |
| 17. | ALA3535049 | ADME | Activity of recombinant human CYP2A6 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated metabolite formation at 10 uM after 60 mins by LC-MS analysis | Homo sapiens | 1 | ALA3525951 | assay format | Scientific Literature | |
| 18. | ALA3536191 | ADME | Activity of recombinant human CYP2A6 expressed in microsomes isolated from baculovirus infected insect cell assessed as enzyme-mediated 2-(2-((R)-3-((1-(carboxymethyl)cyclopropyl)methylthio)-3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)propyl)phenyl)-2-hydroxypropanoic acid formation at 1 uM after 30 mins by LC-MS analysis | Homo sapiens | 1 | ALA3525951 | assay format | Scientific Literature | |
| 19. | ALA3532204 | ADME | Binding affinity to CYP2A6 (unknown origin) assessed as type 2 interaction as increase in absorbance 431 to 432 nm and decrease in 406 to 412 nm | Homo sapiens | 3 | ALA3526117 | single protein format | Scientific Literature | |
| 20. | ALA3532205 | ADME | Binding affinity to CYP2A6 (unknown origin) assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm | Homo sapiens | 6 | ALA3526117 | single protein format | Scientific Literature |
The page will load shortly, Thanks for your patience!